IL150265A0 - Improved pharmaceutical formulations comprising one or more solubilized hiv protease inhibiting compounds - Google Patents

Improved pharmaceutical formulations comprising one or more solubilized hiv protease inhibiting compounds

Info

Publication number
IL150265A0
IL150265A0 IL15026500A IL15026500A IL150265A0 IL 150265 A0 IL150265 A0 IL 150265A0 IL 15026500 A IL15026500 A IL 15026500A IL 15026500 A IL15026500 A IL 15026500A IL 150265 A0 IL150265 A0 IL 150265A0
Authority
IL
Israel
Prior art keywords
hiv protease
inhibiting compounds
protease inhibiting
pharmaceutical formulations
improved pharmaceutical
Prior art date
Application number
IL15026500A
Other languages
English (en)
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23936923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL150265(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of IL150265A0 publication Critical patent/IL150265A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
IL15026500A 2000-01-19 2000-12-01 Improved pharmaceutical formulations comprising one or more solubilized hiv protease inhibiting compounds IL150265A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48773900A 2000-01-19 2000-01-19
PCT/US2000/032771 WO2001052821A1 (en) 2000-01-19 2000-12-01 Improved pharmaceutical formulations

Publications (1)

Publication Number Publication Date
IL150265A0 true IL150265A0 (en) 2002-12-01

Family

ID=23936923

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15026500A IL150265A0 (en) 2000-01-19 2000-12-01 Improved pharmaceutical formulations comprising one or more solubilized hiv protease inhibiting compounds
IL150265A IL150265A (en) 2000-01-19 2002-06-17 Pharmaceutical compounds including ritanavir and an organic solvent containing long-chain fatty acid and propylene glycol

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150265A IL150265A (en) 2000-01-19 2002-06-17 Pharmaceutical compounds including ritanavir and an organic solvent containing long-chain fatty acid and propylene glycol

Country Status (26)

Country Link
EP (3) EP1248600B1 (xx)
JP (1) JP4769400B2 (xx)
KR (1) KR100861885B1 (xx)
CN (1) CN100536833C (xx)
AT (1) ATE395049T1 (xx)
AU (2) AU1940501A (xx)
BG (1) BG66112B1 (xx)
BR (1) BR0011864A (xx)
CA (1) CA2395987C (xx)
CY (3) CY1108197T1 (xx)
CZ (1) CZ304118B6 (xx)
DE (1) DE60038899D1 (xx)
DK (3) DK1917958T3 (xx)
ES (3) ES2676151T3 (xx)
HK (1) HK1120213A1 (xx)
HU (1) HU229778B1 (xx)
IL (2) IL150265A0 (xx)
MX (1) MXPA02007097A (xx)
NO (1) NO331400B1 (xx)
NZ (1) NZ519724A (xx)
PT (3) PT2269591T (xx)
SI (3) SI1917958T1 (xx)
SK (1) SK287143B6 (xx)
TR (1) TR201809435T4 (xx)
WO (1) WO2001052821A1 (xx)
ZA (1) ZA200205109B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359945C (en) 1999-11-12 2011-04-26 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
GB0615211D0 (en) * 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
WO2009019661A1 (en) * 2007-08-07 2009-02-12 Ranbaxy Laboratories Limited Process for preparation of amorphous lopinavir
US9096556B2 (en) 2011-05-27 2015-08-04 Hetero Research Foundation Amorphous ritonavir co-precipitated
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US594836A (en) * 1897-11-30 Corner-brace
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
DK0813867T3 (da) 1990-11-19 2005-10-03 Monsanto Co Retrovirale proteaseinhibitorer
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
EP0765873B1 (en) 1991-10-11 2002-04-17 Dupont Pharmaceuticals Company Cyclic ureas and analogues useful as retroviral protease inhibitors
ES2112880T3 (es) 1991-11-08 1998-04-16 Merck & Co Inc Inhibidores de la proteasa de vih utiles para el tratamiento del sida.
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
ATE116640T1 (de) 1992-03-13 1995-01-15 Bio Mega Boehringer Ingelheim Substituierte pipecoline-säurederivate als hiv- protease-hemmer.
AU4253193A (en) 1992-05-20 1993-12-13 G.D. Searle & Co. Urea-containing hydroxyethylamine compounds as retroviral protease inhibitors
US5559256A (en) 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
CA2502856C (en) 1992-12-29 2009-01-20 Abbott Laboratories Intermediates for retroviral protease inhibiting compounds
WO1995006061A1 (en) 1993-08-20 1995-03-02 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US5567823A (en) 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2238977A1 (en) * 1995-12-13 1997-06-19 Abbott Laboratories Retroviral protease inhibiting compounds
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
KR100815412B1 (ko) * 1999-06-04 2008-03-20 아보트 러보러터리즈 개선된 약제학적 제형

Also Published As

Publication number Publication date
CA2395987C (en) 2009-12-22
BG106976A (bg) 2003-05-30
IL150265A (en) 2015-02-26
EP1917958A3 (en) 2008-08-27
CY1112995T1 (el) 2016-04-13
PT1917958E (pt) 2012-08-16
CY1108197T1 (el) 2014-02-12
DK1917958T3 (da) 2012-09-24
EP1917958A2 (en) 2008-05-07
CY1120408T1 (el) 2019-07-10
AU1940501A (en) 2001-07-31
AU2006235895B2 (en) 2009-08-13
SI2269591T1 (en) 2018-08-31
CN100536833C (zh) 2009-09-09
ES2304990T3 (es) 2008-11-01
SI1917958T1 (sl) 2012-10-30
EP2269591A2 (en) 2011-01-05
JP4769400B2 (ja) 2011-09-07
PT1248600E (pt) 2008-08-25
JP2003533435A (ja) 2003-11-11
SK11102002A3 (sk) 2002-12-03
CZ304118B6 (cs) 2013-11-06
HUP0302070A2 (hu) 2003-09-29
HU229778B1 (hu) 2014-07-28
CN1424907A (zh) 2003-06-18
EP1917958B1 (en) 2012-06-13
DK1248600T3 (da) 2008-09-08
ES2676151T3 (es) 2018-07-17
ATE395049T1 (de) 2008-05-15
HUP0302070A3 (en) 2007-02-28
ZA200205109B (en) 2003-10-31
CA2395987A1 (en) 2001-07-26
PT2269591T (pt) 2018-07-09
CZ20022663A3 (cs) 2002-11-13
NO331400B1 (no) 2011-12-19
HK1120213A1 (en) 2009-03-27
BG66112B1 (bg) 2011-05-31
WO2001052821A1 (en) 2001-07-26
KR100861885B1 (ko) 2008-10-09
SI1248600T1 (sl) 2008-08-31
KR20020082210A (ko) 2002-10-30
EP2269591A3 (en) 2011-07-27
AU2006235895A1 (en) 2006-11-30
NZ519724A (en) 2004-07-30
NO20023455D0 (no) 2002-07-18
SK287143B6 (sk) 2010-01-07
MXPA02007097A (es) 2003-01-28
NO20023455L (no) 2002-09-18
BR0011864A (pt) 2004-07-20
ES2387579T3 (es) 2012-09-26
DK2269591T3 (en) 2018-07-16
TR201809435T4 (tr) 2018-07-23
EP2269591B1 (en) 2018-04-04
DE60038899D1 (de) 2008-06-26
EP1248600A1 (en) 2002-10-16
PL361396A1 (en) 2004-10-04
EP1248600B1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
CY1105237T1 (el) Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir
MX265024B (es) Formulaciones de glifosato de potasio.
HK1120213A1 (en) Improved hiv protease inhibitors pharmaceutical formulations
HK1036935A1 (en) Pharmaceutical compositions.
MXPA03005579A (es) Composiciones de alchol primario ramificado y derivados del mismo.
ZA200102769B (en) Opthalmic formulations.
MXPA02012891A (es) Composiciones farmaceuticas de agentes estrogenicos.
HUP0300720A3 (en) Serine protease inhibitors, pharmaceutical compositions containing them and their use
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
ZA200210359B (en) Pharmaceutical compositions.
IL145635A0 (en) Taxane formulations having improved solubility
MXPA03002105A (es) Composiciones farmaceuticas.
IL126185A0 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
SE0001916D0 (sv) Novel formulation
CY2444B1 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs.
GB0011734D0 (en) Pharmaceutical composition for anthelmintics (1)